Patents by Inventor Hartwig Steckel

Hartwig Steckel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11185475
    Abstract: Biomaterials, in particular bone foams, a process for preparing such materials as well as an applicator for applying the biomaterials directly to the patient's application site, and the use of a composition comprising water, a surfactant and a propellant in the preparation of a bone foam for the preparation of a calcium phosphate foam wherein the foam is obtainable by the mixture of at least two phases, a first phase comprising water and optionally a propellant, a second phase comprising one or more sources for calcium and/or phosphate, and wherein the foaming is performed during the mixture of the at least two phases to provide an improved calcium phosphate foam, process for the preparation of a calcium phosphate foam, use of a composition, solid state structure, calcium phosphate cement foam and bone foam applicator.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: November 30, 2021
    Assignee: Stryker European Operations Holdings LLC
    Inventors: Hartwig Steckel, Maren Kuhli, Torben Christian Sörensen, Nils Reimers
  • Patent number: 10864297
    Abstract: A method of manufacturing an implant for use in a surgical procedure, a corresponding implant and the use thereof during the incorporation of a substance is presented. Specifically anodized and blasted titanium implant substrates are provided with a hydroxyapatite (HA) coating for incorporating for example a therapeutic agent. In particular, an anodizing procedure by an electrolytic process in an alkaline liquid is carried out. Moreover, blasting of the anodized titanium implant substrate is carried out by the presented method. The HA coating can be in the range of 1 to 5 ?m, particularly in the range of 1 to 3 ?m. A local delivery of the active pharmaceutical ingredient is achieved by the implant of the present invention. Moreover, the implant allows for the removal of the implant without damaging surrounding tissue or a bone. Moreover, the HA coating is provided to the substrate such that enhanced fixation as measured by pull-out force is achieved whilst having a relatively low removal torque.
    Type: Grant
    Filed: September 2, 2013
    Date of Patent: December 15, 2020
    Inventors: Philip Procter, Jan Henrik Sörensen, Hartwig Steckel, Torben Christian Sörensen, Ken Welch
  • Patent number: 10588957
    Abstract: The present invention relates to a method for producing stabilised vaccines, the method comprising: (a) mixing antigens with a solution comprising: (i) chitosan; (ii) at least three different amino acids and/or at least one dipeptide or tripeptide; and (iii) a sugar; and (b) drying the mixture obtained in (a).
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: March 17, 2020
    Assignee: LEUKOCARE AG
    Inventors: Martin Scholz, Jens Altrichter, Kristina Kemter, Regina Scherliess, Hartwig Steckel
  • Patent number: 10369217
    Abstract: The present invention is directed to nanoparticles comprising chitosan and an antigen, whereby the chitosan has a degree of deacetylation of about 90% and a molecular weight from 5 kDa to 80 kDa, to microparticles containing such nanoparticles as well as to a process for preparation of such particles. The particles are usable for vaccination.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: August 6, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Andrea Hanefeld, Markus Weigandt, Michael Wolf, Percy Knolle, Matthias Schroeder, Regina Scherliess, Peter Walden, Andrea Diedrich, Hartwig Steckel, Renato Brito Baleeiro
  • Publication number: 20190105238
    Abstract: Biomaterials, in particular bone foams, a process for preparing such materials as well as an applicator for applying the biomaterials directly to the patient's application site, and the use of a composition comprising water, a surfactant and a propellant in the preparation of a bone foam for the preparation of a calcium phosphate foam wherein the foam is obtainable by the mixture of at least two phases, a first phase comprising water and optionally a propellant, a second phase comprising one or more sources for calcium and/or phosphate, and wherein the foaming is performed during the mixture of the at least two phases to provide an improved calcium phosphate foam, process for the preparation of a calcium phosphate foam, use of a composition, solid state structure, calcium phosphate cement foam and bone foam applicator.
    Type: Application
    Filed: December 5, 2018
    Publication date: April 11, 2019
    Inventors: Hartwig Steckel, Maren Kuhli, Torben Christian Sörensen, Nils Reimers
  • Patent number: 10182973
    Abstract: Biomaterials, in particular bone foams, a process for preparing such materials as well as an applicator for applying the biomaterials directly to the patient's application site, and the use of a composition comprising water, a surfactant and a propellant in the preparation of a bone foam for the preparation of a calcium phosphate foam wherein the foam is obtainable by the mixture of at least two phases, a first phase comprising water and optionally a propellant, a second phase comprising one or more sources for calcium and/or phosphate, and wherein the foaming is performed during the mixture of the at least two phases to provide an improved calcium phosphate foam, process for the preparation of a calcium phosphate foam, use of a composition, solid state structure, calcium phosphate cement foam and bone foam applicator.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: January 22, 2019
    Assignee: Stryker European Holdings I, LLC
    Inventors: Hartwig Steckel, Maren Kuhli, Torben Christian Sörensen, Nils Reimers
  • Publication number: 20180339036
    Abstract: The present invention relates to a method for producing stabilised vaccines, the method comprising: (a) mixing antigens with a solution comprising: (i) chitosan; (ii) at least three different amino acids and/or at least one dipeptide or tripeptide; and (iii) a sugar; and (b) drying the mixture obtained in (a).
    Type: Application
    Filed: October 24, 2014
    Publication date: November 29, 2018
    Inventors: Martin Scholz, Jens Altrichter, Kristina Kemter, Regina Scherliess, Hartwig Steckel
  • Patent number: 9919077
    Abstract: A method for co-precipitating a therapeutic agent into a hydroxyapatite coated surface includes the steps of providing a surface and applying a hydroxyapatite seed layer on the surface. The hydroxyapatite seed layered surface is contacted with a solution including the therapeutic agent and a co-precipitated therapeutic agent, hydroxyapatite layer is formed on the coated surface to uniformly distribute the therapeutic agent in the layer. Further, an implant having sustained therapeutic agent delivery includes a base and an hydroxyapatite seed layer disposed on a surface of the base. A co-precipitated hydroxyapatite coating is disposed on the seed layer. The coating includes a therapeutic agent, wherein the therapeutic agent is provided in a solution of therapeutic agent.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: March 20, 2018
    Assignee: Stryker European Holdings I, LLC
    Inventors: Mirjam Lilja, Philip Procter, Hartwig Steckel, Torben Christian Sörensen, Jan Soerensen
  • Patent number: 9731021
    Abstract: The present patent application is related to a hydrogel composition which is essentially free of active drugs for the manufacture of a product for the treatment of dermatological disorders, especially perioral dermatitis, acne or seborrheic dermatitis.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: August 15, 2017
    Assignee: INTENDIS GMBH
    Inventors: Hartwig Steckel, Karin Hoffmann
  • Patent number: 9662425
    Abstract: A method for loading a hydroxyapatite coated implant with a therapeutic agent including the steps of providing an implant and applying a hydroxyapatite coating on a surface of the implant. The hydroxyapatite coated implant is contacted with a solution including the therapeutic agent. The hydroxyapatite coated implant and solution is heated to temperature of about 60° C. to about 100° C. Pressure is applied to the hydroxyapatite coated implant and solution from about 2 bar to about 10 bar, to load the hydroxyapatite coated implant with the therapeutic agent. An implant made according to the method has sustained therapeutic agent delivery and includes a base and a biomimetic hydroxyapatite coating disposed on a surface thereof.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: May 30, 2017
    Assignee: Stryker European Holdings I, LLC
    Inventors: Mirjam Lilja, Jan Henrik Sörensen, Philip Procter, Hartwig Steckel, Torben Christian Sörensen
  • Publication number: 20170143822
    Abstract: The present invention is directed to nanoparticles comprising chitosan and an antigen, whereby the chitosan has a degree of deacetylation of about 90% and a molecular weight from 5 kDa to 80 kDa, to microparticles containing such nanoparticles as well as to a process for preparation of such particles. The particles are usable for vaccination.
    Type: Application
    Filed: May 12, 2015
    Publication date: May 25, 2017
    Applicant: MERCK PATENT GMBH
    Inventors: Andrea HANEFELD, Markus WEIGANDT, Michael WOLF, Percy KNOLLE, Matthias SCHROEDER, Regina SCHERLIESS, Peter WALDEN, Andrea DIEDRICH, Hartwig STECKEL, Renato Brito BALEEIRO
  • Publication number: 20160220730
    Abstract: A method of manufacturing an implant for use in a surgical procedure, a corresponding implant and the use thereof during the incorporation of a substance is presented. Specifically anodized and blasted titanium implant substrates are provided with a hydroxyapatite (HA) coating for incorporating for example a therapeutic agent. In particular, an anodizing procedure by an electrolytic process in an alkaline liquid is carried out. Moreover, blasting of the anodized titanium implant substrate is carried out by the presented method. The HA coating can be in the range of 1 to 5 ?m, particularly in the range of 1 to 3 ?m. A local delivery of the active pharmaceutical ingredient is achieved by the implant of the present invention. Moreover, the implant allows for the removal of the implant without damaging surrounding tissue or a bone. Moreover, the HA coating is provided to the substrate such that enhanced fixation as measured by pull-out force is achieved whilst having a relatively low removal torque.
    Type: Application
    Filed: September 2, 2013
    Publication date: August 4, 2016
    Inventors: Philip Procter, Jan Henrik Söerensen, Hartwig Steckel, Torben Christian Sörensen, Ken Welch
  • Publication number: 20160144070
    Abstract: A method for co-precipitating a therapeutic agent into a hydroxyapatite coated surface includes the steps of providing a surface and applying a hydroxyapatite seed layer on the surface. The hydroxyapatite seed layered surface is contacted with a solution including the therapeutic agent and a co-precipitated therapeutic agent, hydroxyapatite layer is formed on the coated surface to uniformly distribute the therapeutic agent in the layer. Further, an implant having sustained therapeutic agent delivery includes a base and an hydroxyapatite seed layer disposed on a surface of the base. A co-precipitated hydroxyapatite coating is disposed on the seed layer. The coating includes a therapeutic agent, wherein the therapeutic agent is provided in a solution of therapeutic agent.
    Type: Application
    Filed: June 19, 2014
    Publication date: May 26, 2016
    Inventors: Mirjam Lilja, Philip Procter, Hartwig Steckel, Torben Christian Sörensen, Jan Soerensen
  • Publication number: 20160058922
    Abstract: A method for loading a hydroxyapatite coated implant with a therapeutic agent including the steps of providing an implant and applying a hydroxyapatite coating on a surface of the implant. The hydroxyapatite coated implant is contacted with a solution including the therapeutic agent. The hydroxyapatite coated implant and solution is heated to temperature of about 60° C. to about 100° C. Pressure is applied to the hydroxyapatite coated implant and solution from about 2 bar to about 10 bar, to load the hydroxyapatite coated implant with the therapeutic agent. An implant made ac cording to the method has sustained therapeutic agent delivery and includes a base and a biomimetic hydroxyapatite coating disposed on a surface thereof.
    Type: Application
    Filed: April 22, 2014
    Publication date: March 3, 2016
    Inventors: Mirjam Lilja, Jan Henrik Sörensen, Philip Procter, Hartwig Steckel, Torben Christian Sörensen
  • Publication number: 20150182630
    Abstract: The present patent application is related to a hydrogel composition which is essentially free of active drugs for the manufacture of a product for the treatment of dermatological disorders, especially perioral dermatitis, acne or seborrheic dermatitis.
    Type: Application
    Filed: November 14, 2014
    Publication date: July 2, 2015
    Applicant: INTENDIS GMBH
    Inventors: Hartwig STECKEL, Karin HOFFMANN
  • Publication number: 20140012271
    Abstract: Biomaterials, in particular bone foams, a process for preparing such materials as well as an applicator for applying the biomaterials directly to the patient's application site, and the use of a composition comprising water, a surfactant and a propellant in the preparation of a bone foam for the preparation of a calcium phosphate foam wherein the foam is obtainable by the mixture of at least two phases, a first phase comprising water and optionally a propellant, a second phase comprising one or more sources for calcium and/or phosphate, and wherein the foaming is performed during the mixture of the at least two phases to provide an improved calcium phosphate foam, process for the preparation of a calcium phosphate foam, use of a composition, solid state structure, calcium phosphate cement foam and bone foam applicator.
    Type: Application
    Filed: November 10, 2010
    Publication date: January 9, 2014
    Applicant: STRYKER TRAUMA GMBH
    Inventors: Hartwig Steckel, Maren Kuhli, Torben Christian Sörensen, Nils Reimers
  • Publication number: 20130150370
    Abstract: Pharmaceutical composition for oral administration comprises at least one phosphodiesterase inhibitor and at least one sugar alcohol selected from mannitol, sorbitol, xylitol, maltitol, lactitol, erythritol, threitol and Isomalt, and sodium hydrogen carbonate as pharmaceutical excipients in the following weight proportions: phosphodiesterase inhibitor: about 10 to about 150 parts by weight in total; sugar alcohol: about 50 to about 600 parts by weight in total; and sodium hydrogen carbonate: about 2 to about 100 parts by weight. The above composition for use in a method of treating male erectile dysfunction with an accelerated onset of action is also disclosed.
    Type: Application
    Filed: June 24, 2011
    Publication date: June 13, 2013
    Inventor: Hartwig Steckel
  • Patent number: 8282909
    Abstract: The present invention provides a formulation which contains a poorly water soluble pharmaceutically active compound at a concentration of 50 mg per 100 g formulation or above. The solubility is achieved by a mixture of solvents as described herein. Moreover the formulation as described herein may be used as a base formulation to generate a cream, an ointment, a spray, a foam or an oleogel.
    Type: Grant
    Filed: July 9, 2008
    Date of Patent: October 9, 2012
    Assignee: Intendis GmbH
    Inventors: Hartwig Steckel, Karin Hoffmann
  • Publication number: 20110190245
    Abstract: The present invention is directed to new nanosuspensions of antifungal azole derivatives, particularly itraconazole, with with improved impurity profile optimized for inhaled administration for the prevention, reversal and medical treatment of fungal infections of the respiratory tract including adjacent lymph nodes. The new formulation which is devoid of particulate inorganic contamination can be safely administered by inhalation. This administration route results in an improved therapeutic effect and reduced side effect profile as compared to the previously used clinical administration route, i.e. oral or parenteral (intravenous) administration.
    Type: Application
    Filed: February 26, 2009
    Publication date: August 4, 2011
    Inventors: Chris Rundfeldt, Hartwig Steckel, Holger Scherliess
  • Publication number: 20110159102
    Abstract: The disclosure relates to a process for continuously producing spherical powder agglomerates, in which morphologically irregular starting agglomerates of micronized pulverulent particles are rounded off continuously by application to a surface induced to vibrate.
    Type: Application
    Filed: October 13, 2008
    Publication date: June 30, 2011
    Applicant: Pharmatech GmbH
    Inventors: Thorsten Hartmann, Bernd W. Müller, Hartwig Steckel